PDX Portal

Model Details

Patient Information for Model: TCH-AML002

Model Contact

Model: TCH-AML002
Model Contact: Michele Redell
Institution: TCH Leukemia PDX Program
Email: mlredell@texaschildrens.org

Patient Information

Clinical Timeline

Clinical Information at Collection

Clinical Biomarkers/Mutations

Model Information for Model: TCH-AML002

Model Details - Initial Implantation of Patient Tissue

Mutations (Cancer Gene Census List)

Mutation data is currently not available.

CNV

There are no omics data for this model.

Histology Information for Model: TCH-AML002

There are no histology images for this model.

Metastasis Information for Model: TCH-AML002

Patient

PDX

Central Nervous System

Face

Gingiva

Liver

Lymph node

Orbital chloroma

Retinas

Skin

Spleen

Testis

Tongue

Patient Treatment Information for Model: TCH-AML002

Event Id	Treatment	Treatment Setting	Age at Start	Duration	Clinical Response	Measurable Residual Disease
10	Cytarabine/Idarubicin	De Novo	20.06	1Unknown	Induction Failure
15	Cytarabine/Fludarabine	Refractory	20.25	1Unknown	Residual Disease
20	clo/topotecan/vinorelbine/thiotepa	Refractory	20.37	1Unknown	Residual Disease
25	azacitidine/venetoclax	Refractory	20.54	1Unknown
30	venetoclax	Refractory	20.66	1Unknown	Remission	.16%
50	decitabine/venetoclax then DLI	Relapse	21.3	1Unknown	Relapse	14%
60	decitabine/venetoclax then DLI	Relapse	21.4	1Unknown	Relapse	4%